• Corpus ID: 190868005

Anti-Inflammatory Effects of Heparin: Do they Influence Murine Acute GvHD?

@inproceedings{Budde2015AntiInflammatoryEO,
  title={Anti-Inflammatory Effects of Heparin: Do they Influence Murine Acute GvHD?},
  author={Holger Budde and Lena Thieringer and Joachim Riggert and Tobias J. Legler},
  year={2015}
}
Anti-Inflammatory Effects of Heparin: Do they Influence Murine Acute GvHD? Holger Budde1*, Lena Thieringer1, Joachim Riggert1, Tobias J Legler1 1Department of Transfusion Medicine, University Medical Center Göttingen, Göttingen, Germany *Corresponding author: Dr. Holger Budde, Department of Transfusion Medicine, University Medical Center Göttingen, Robert-KochStr. 40, 37075 Göttingen, Germany, Tel : +49 551 39 12946; E-Mail: holger.budde@med.uni-goettingen.de Received: 11-16-2015 Accepted: 11… 
goedoc.uni-goettingen.de

Figures from this paper

27 References

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions

Both intranasal heparin and lmw heparIn treatment decreased the expression of Th1, Th2, and Th17 in spleen, and the analyses of mRNA and cytokines revealed that both intraneasal and low-molecular-weightHeparin treatment decreasedThe underlying mechanism(s) warrant further studies.

Low-dose heparin inhibits acute graft versus host disease in mice.

It is shown that heparin in low doses attenuates the severity of acute GVHD and reduces the mortality rate from 69 to 37.5% without abrogating the GVL effect induced by the allograft and without impairing marrow engraftment.

Concentration-dependent roles for heparin in modifying liopolysaccharide-induced activation of mononuclear cells in whole blood

It is demonstrated that in the absence of LBP, the direct effect of heparin on LPS-stimulated monocytes is anti-inflammatory, however in whole blood, the immunomodulatory effects ofheparin are significantly more complex, with either pro- or anti- inflammatory effects dependent upon heparIn concentration.

Steroid‐refractory graft‐vs.‐host disease: past, present and future

Promising new agents or strategies which warrant further controlled clinical trials include: mycophenolate mofetil, sirolimus, humanized or chimeric monoclonal antibodies such as visilizumab, daclizuab and infliximab, and extracorporeal photopheresis.

Low‐molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor‐κB in LPS‐stimulated human monocytes

Results indicate equivalent and significant heparin anti‐inflammatory properties at low doses on monocyte‐mediated immune response and LMWH and UFH appear as potential therapeutic inhibitors of inflammation.

A comparison of the influence of parenteral trypsin, cortisone, and heparin on acute inflammation.

Clinical observations based on 6,456trypsin infusions to 538 patients supporting the view that trypsin rapidly suppresses acute inflammation of diversified origin are presented.

Treatment of corticosteroid‐resistant ulcerative colitis with heparin —a report of 16 cases

Heparin, a group of sulphated glycosaminoglycans, has a wide range of potentially anti‐inflammatory effects, including inhibition of neutrophil elastase and inactivation of chemokines, which prompted this pilot study in patients with corticosteroid‐resistant ulcerative colitis.

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?

    F. Al-Eidan
    Medicine, Biology
    Mediterranean journal of hematology and infectious diseases
  • 2015
The increased trend of using LMWH over UFH among hospitalized adult patients was observed and can be said to contribute to the diminished overall incidence of HIT.

The anti-inflammatory effects of heparin and related compounds.

    E. Young
    Biology, Chemistry
    Thrombosis research
  • 2008

Low Molecular Weight Heparin Relieves Experimental Colitis in Mice by Downregulating IL-1β and Inhibiting Syndecan-1 Shedding in the Intestinal Mucosa

LMWH has therapeutic effects on colitis by downregulating inflammatory cytokines and inhibiting syndecan-1 shedding in the intestinal mucosa and significantly decreased the expression of both IL-1β and IL-10 mRNA on days 12 and 20 after DSS administration.